Mite Trial Failure 'The Final Straw' As Circassia Ends Anti-Allergy Investing
Executive Summary
Circassia has thrown in the towel on investing in anti-allergy vaccines and will focus now on respiratory activities, after its house dust mite allergy study missed its primary endpoints.
You may also be interested in...
Stallergenes' Mite Allergy Results An Early Leaving Present For Retiring CEO
Positive Phase III data with its sublingual house dust allergy tablet heralds a likely increase in competition in the US allergy sector in the years to come and also provide an early leaving present for the company's retiring CEO.
The Value Of Being Decisive On Strategic Needs – Through One Pharma CEO's Lens
After a promising research program failed to deliver, London-listed Circassia changed from being an R&D-based allergy company to one focused on commercial respiratory therapies. Rapid decision-making averted a crisis and earned the company a US deal and equity partnership with AstraZeneca. As an exercise in Plan B readiness, it's surely up there with the best.
LAMA/LABA Combo Duaklir Moves Closer To US Filing
AstraZeneca has released positive top-line data from a new Phase III study of the LAMA/LABA combination, Duaklir, in COPD that could lead to a US NDA filing in 2018, and the start of US marketing by partner Circassia.